iAnthus Capital Holdings, Inc.

DB:2IA Stock Report

Market Cap: €45.8m

iAnthus Capital Holdings Past Earnings Performance

Past criteria checks 0/6

iAnthus Capital Holdings has been growing earnings at an average annual rate of 20.3%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 8.9% per year.

Key information

20.3%

Earnings growth rate

59.4%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate8.9%
Return on equityn/a
Net Margin-32.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How iAnthus Capital Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:2IA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24165-54740
30 Jun 24168-62730
31 Mar 24163-72770
31 Dec 23158-77780
30 Sep 23155-102730
30 Jun 23152-104810
31 Mar 23157-4581090
31 Dec 22163-4491140
30 Sep 22172-4331200
30 Jun 22182-4261210
31 Mar 22193-68970
31 Dec 21202-77970
30 Sep 21201-77860
30 Jun 21193-87870
31 Mar 21173-96870
31 Dec 20152-313920
30 Sep 20133-547950
30 Jun 20115-5341030
31 Mar 2099-5191080
31 Dec 1978-305950
30 Sep 1953-61850
30 Jun 1932-58610
31 Mar 1913-84430
31 Dec 183-62350
30 Sep 180-53270
30 Jun 180-45220
31 Mar 180-12140
31 Dec 170-14100
30 Sep 172-880
30 Jun 171-870
31 Mar 171-650
31 Dec 160-540
30 Sep 160-440
31 Dec 150-110

Quality Earnings: 2IA is currently unprofitable.

Growing Profit Margin: 2IA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2IA is unprofitable, but has reduced losses over the past 5 years at a rate of 20.3% per year.

Accelerating Growth: Unable to compare 2IA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2IA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).


Return on Equity

High ROE: 2IA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies